BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCompany update

SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee. As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise

Related news

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

ANVSAnnovis Bio2026-07-01 12:00 EST

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

VKTXViking Therapeutics2026-07-23 11:05 EST

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-23 20:05 EST

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

NBIXNeurocrine Biosciences2026-07-21 20:05 EST

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Stock data

Close
159.82 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States